Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis
Bristol Myers Squibb (NYSE: BMY) announced positive results from two pivotal Phase 3 trials, POETYK PsA-1 and POETYK PsA-2, evaluating Sotyktu (deucravacitinib) in adults with active psoriatic arthritis. Both trials met their primary endpoint, with significantly more Sotyktu-treated patients achieving ACR20 response (20% improvement in disease symptoms) after 16 weeks compared to placebo.
The trials also met important secondary endpoints across PsA disease activity at Week 16. The safety profile remained consistent with previous Phase 2 PsA and Phase 3 plaque psoriasis trials. These results represent the first Phase 3 trials for Sotyktu in a rheumatic condition, with the drug already approved globally for moderate-to-severe plaque psoriasis treatment.
Bristol Myers Squibb (NYSE: BMY) ha annunciato risultati positivi provenienti da due studi pivotal di Fase 3, POETYK PsA-1 e POETYK PsA-2, che valutano Sotyktu (deucravacitinib) negli adulti con artrite psoriasica attiva. Entrambi gli studi hanno raggiunto il loro obiettivo primario, con un numero significativamente maggiore di pazienti trattati con Sotyktu che ha ottenuto una risposta ACR20 (miglioramento del 20% nei sintomi della malattia) dopo 16 settimane rispetto al gruppo placebo.
Gli studi hanno anche raggiunto importanti obiettivi secondari riguardanti l'attività della malattia PsA alla Settimana 16. Il profilo di sicurezza è rimasto coerente con quelli precedenti degli studi di Fase 2 su PsA e degli studi di Fase 3 sulla psoriasi a placche. Questi risultati rappresentano i primi studi di Fase 3 per Sotyktu in una condizione reumatica, con il farmaco già approvato a livello globale per il trattamento della psoriasi a placche di gravità moderata-severa.
Bristol Myers Squibb (NYSE: BMY) anunció resultados positivos de dos ensayos clínicos pivotal de Fase 3, POETYK PsA-1 y POETYK PsA-2, que evaluaron Sotyktu (deucravacitinib) en adultos con artritis psoriásica activa. Ambos ensayos cumplieron con su objetivo primario, con significativamente más pacientes tratados con Sotyktu logrando una respuesta ACR20 (mejora del 20% en los síntomas de la enfermedad) después de 16 semanas en comparación con placebo.
Los ensayos también cumplieron con objetivos secundarios importantes en relación con la actividad de la enfermedad PsA en la Semana 16. El perfil de seguridad se mantuvo consistente con ensayos previos de Fase 2 en PsA y ensayos de Fase 3 en psoriasis en placas. Estos resultados representan los primeros ensayos de Fase 3 para Sotyktu en una condición reumática, con el medicamento ya aprobado a nivel global para el tratamiento de la psoriasis en placas moderada a severa.
브리스톨 마이어스 스퀴브 (NYSE: BMY)는 활성 건선 관절염 성인의 소티크투 (데우크라바시티닙)을 평가하는 두 개의 주요 3상 임상시험, POETYK PsA-1 및 POETYK PsA-2에서 긍정적인 결과를 발표했습니다. 두 시험 모두 주요 목표를 달성했으며, 소티크투 치료를 받은 환자들 중 많은 수가 16주 후에 플라세보 그룹과 비교하여 ACR20 응답(질병 증상 20% 개선)에 도달했습니다.
이 또한 PsA 질병 활동의 유의미한 이차 목표를 16주 차에 충족했습니다. 안전성 프로파일은 이전의 2상 PsA 및 3상 판상 건선 임상시험과 일관되게 유지되었습니다. 이러한 결과는 소티크투의 첫 번째 3상 시험이 재생불량성 질환에 대한 것으로, 이 약물은 이미 중등도에서 중증 판상 건선 치료를 위해 전 세계적으로 승인되었습니다.
Bristol Myers Squibb (NYSE: BMY) a annoncé des résultats positifs de deux essais pivot de phase 3, POETYK PsA-1 et POETYK PsA-2, évaluant Sotyktu (deucravacitinib) chez des adultes atteints d'arthrite psoriasique active. Les deux essais ont atteint leur objectif principal, avec un nombre significativement plus élevé de patients traités par Sotyktu atteignant une réponse ACR20 (amélioration de 20% des symptômes de la maladie) après 16 semaines par rapport au placebo.
Les essais ont également atteint des objectifs secondaires importants concernant l'activité de la maladie PsA à la semaine 16. Le profil de sécurité est resté cohérent avec ceux des essais de phase 2 sur la PsA et des essais de phase 3 sur le psoriasis en plaques. Ces résultats représentent les premiers essais de phase 3 pour Sotyktu dans une affection rhumatologique, le médicament étant déjà approuvé à l'échelle mondiale pour le traitement du psoriasis en plaques modéré à sévère.
Bristol Myers Squibb (NYSE: BMY) hat positive Ergebnisse aus zwei entscheidenden Phase-3-Studien, POETYK PsA-1 und POETYK PsA-2, bekannt gegeben, die Sotyktu (Deucravacitinib) bei Erwachsenen mit aktiver Psoriasis-Arthritis bewerten. Beide Studien erfüllten ihr primäres Ziel, wobei signifikant mehr Patienten, die mit Sotyktu behandelt wurden, nach 16 Wochen im Vergleich zur Placebogruppe eine ACR20-Ansprechrate (20% Verbesserung der Krankheitssymptome) erreichten.
Die Studien erreichten ebenfalls wichtige sekundäre Endpunkte bezüglich der PsA-Krankheitsaktivität in Woche 16. Das Sicherheitsprofil blieb konsistent mit früheren Phase-2- und Phase-3-Studien zu Plaque-Psoriasis. Diese Ergebnisse stellen die ersten Phase-3-Studien für Sotyktu in einer rheumatischen Erkrankung dar, wobei das Medikament bereits global für die Behandlung von moderater bis schwerer Plaque-Psoriasis genehmigt ist.
- Both Phase 3 trials met primary endpoint showing significant improvement in disease symptoms
- Trials successfully met secondary endpoints for PsA disease activity
- Safety profile consistent with previous trials, indicating reliable safety record
- Potential to be first TYK2 inhibitor for psoriatic arthritis treatment
- None.
Insights
The Phase 3 POETYK PsA-1 and PsA-2 trials represent a significant breakthrough in the treatment landscape for psoriatic arthritis. The achievement of ACR20 response with Sotyktu (deucravacitinib) marks the potential emergence of the first TYK2 inhibitor for PsA treatment. This novel mechanism of action differentiates it from existing oral treatments.
The trial success carries substantial implications:
- Market Expansion: Sotyktu is already approved for plaque psoriasis and this potential new indication could significantly expand its commercial reach
- Treatment Innovation: An oral medication with a novel mechanism provides an alternative to injectable biologics
- Competitive Advantage: Being first-in-class for PsA could give BMY a significant market advantage
The consistent safety profile across multiple trials strengthens the drug's positioning. The global PsA market, valued at approximately
These positive Phase 3 results could significantly impact BMY's revenue potential. Sotyktu, already approved for psoriasis, generated
- PsA affects about
30% of psoriasis patients - The oral administration route is preferred by many patients over injectables
- Strong pricing power as a first-in-class therapy
For context, leading PsA treatments like Humira generated over
POETYK PsA-1 and POETYK PsA-2 trials met primary endpoint, with significantly greater proportion of Sotyktu-treated patients achieving ACR20 response compared with placebo at Week 16
Sotyktu was well-tolerated and demonstrated safety consistent with established profile
Additionally, the POETYK PsA-1 and POETYK PsA-2 trials met important secondary endpoints across PsA disease activity at Week 16. The overall safety profile of Sotyktu through 16 weeks of treatment in the POETYK PsA-1 and POETYK PsA-2 trials was consistent with the established safety profile of Sotyktu observed in a Phase 2 PsA clinical trial and Phase 3 moderate-to-severe plaque psoriasis clinical trials.
"Psoriatic arthritis is a heterogenous disease that causes a range of different symptoms, including joint pain and swelling, as well as psoriatic skin lesions. Despite available therapies, rheumatologists continue to express a need for a safe and effective oral treatment," said Roland Chen, MD, senior vice president and head, Immunology, Cardiovascular and Neuroscience development, Bristol Myers Squibb. "These POETYK PsA-1 and POETYK PsA-2 findings demonstrate that oral Sotyktu has the potential to be the first TYK2 inhibitor for people living with psoriatic arthritis and reinforce the established efficacy and safety profile of Sotyktu. We are encouraged by the positive data across both Phase 3 trials and look forward to discussing the results with health authorities."
Bristol Myers Squibb will work with key investigators to present detailed results at upcoming medical congresses.
These topline results represent the first Phase 3 clinical trials for Sotyktu in a rheumatic condition. Sotyktu is approved in numerous countries around the world for the treatment of adults with moderate-to-severe plaque psoriasis.
Bristol Myers Squibb thanks the patients, investigators and clinical trial sites who participated in these clinical trials.
About the Sotyktu Phase 3 Psoriatic Arthritis Trial Program
The Phase 3 Sotyktu psoriatic arthritis (PsA) program includes two Phase 3, multicenter, randomized, double-blind, placebo-controlled trials evaluating the efficacy and safety in adults 18 years of age and older with active PsA: POETYK PsA-1 (IM011-054; NCT04908202) and POETYK PsA-2 (IM011-055; NCT04908189).
POETYK PsA-1 enrolled approximately 670 patients with active PsA who were not previously treated with a biologic disease-modifying antirheumatic drug (bDMARD naïve). POETYK PsA-2 enrolled approximately 730 patients with active PsA who were bDMARD naïve or had previously received TNFα inhibitor treatment. Both trials include a 52-week treatment period comprised of a placebo-controlled treatment period through Week 16, followed by a reallocation and continued active treatment period from Week 16 to Week 52. POETYK PsA-2 also included an apremilast safety reference arm.
The primary endpoint of both trials was the proportion of participants achieving an ACR20 response at Week 16. Important secondary endpoints were also assessed at Week 16 across measures of PsA disease activity.
Patients in both trials completing 52 weeks of treatment are potentially eligible to enroll in the open-label extension study.
About Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic, immune-mediated, heterogenous disease with multiple musculoskeletal and skin manifestations, including inflammatory arthritis, enthesitis (inflammation where tendon or ligament attaches to the bone), dactylitis (swelling of finger and toe joints) and psoriatic skin and nail lesions. Up to 30 percent of patients with psoriasis will develop PsA. In addition to the loss of physical function, pain and fatigue caused by PsA, the disease can significantly impact the mental and emotional well-being of patients. Patients with PsA are also at increased risk of serious comorbidities, including cardiovascular disease, metabolic syndrome, depression and anxiety.
About Sotyktu (deucravacitinib)
Sotyktu (deucravacitinib) is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action, representing a new class of small molecules. It is the first selective TYK2 inhibitor in clinical studies across multiple immune-mediated diseases. Bristol Myers Squibb scientists designed Sotyktu to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-23, IL-12 and Type 1 interferons (IFN), key cytokines involved in the pathogenesis of multiple immune-mediated diseases. Sotyktu achieves a high degree of selectivity by binding to the regulatory domain of TYK2, resulting in allosteric inhibition of TYK2 and its downstream functions. Sotyktu selectively inhibits TYK2 at physiologically relevant concentrations. At therapeutic doses, Sotyktu does not inhibit JAK1, JAK2 or JAK3.
Sotyktu is approved in numerous countries around the world for the treatment of adults with moderate-to-severe plaque psoriasis.
Bristol Myers Squibb: Pursuing Bold Science in Immunology to Transform Patients’ Lives
Bristol Myers Squibb is inspired by a single vision – transforming patients’ lives through science. For people living with immune-mediated diseases, the debilitating reality of enduring chronic symptoms and disease progression can make simple tasks and daily life a challenge. Driven by our deep understanding of the immune system that spans over 20 years of experience, we continue to pursue bold science as we work to deliver life-changing medicines that elevate new standards of care across rheumatology, dermatology and pulmonology. Our sequential immunotherapy research framework aims to address the root cause of disease by controlling inflammation, resetting the immune system and promoting immune homeostasis with the goal of achieving transformational efficacy. By continuously pushing the boundaries of scientific knowledge, we strive to bring forward tailored approaches, treatments and combinations that may lead to durable remissions, improved quality of life and functional cures. Our collaborations with patients, caregivers, healthcare providers and researchers inform our patient-centric approach as we aim to break efficacy ceilings and deliver what matters most – the promise of living a better life.
SOTYKTU
SOTYKTU® (deucravacitinib) is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Limitations of Use:
SOTYKTU is not recommended for use in combination with other potent immunosuppressants.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
SOTYKTU is contraindicated in patients with a history of hypersensitivity reaction to deucravacitinib or to any of the excipients in SOTYKTU.
WARNINGS AND PRECAUTIONS
Hypersensitivity: Hypersensitivity reactions such as angioedema have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue SOTYKTU.
Infections: SOTYKTU may increase the risk of infections. Serious infections have been reported in patients with psoriasis who received SOTYKTU. The most common serious infections reported with SOTYKTU included pneumonia and COVID-19. Avoid use of SOTYKTU in patients with an active or serious infection. Consider the risks and benefits of treatment prior to initiating SOTYKTU in patients:
- with chronic or recurrent infection
- who have been exposed to tuberculosis
- with a history of a serious or an opportunistic infection
- with underlying conditions that may predispose them to infection.
Closely monitor patients for the development of signs and symptoms of infection during and after treatment. A patient who develops a new infection during treatment should undergo prompt and complete diagnostic testing, have appropriate antimicrobial therapy initiated and be closely monitored. Interrupt SOTYKTU if a patient develops a serious infection. Do not resume SOTYKTU until the infection resolves or is adequately treated.
Viral Reactivation
Herpes virus reactivation (e.g., herpes zoster, herpes simplex) was reported in clinical trials with SOTYKTU. Through Week 16, herpes simplex infections were reported in 17 patients (6.8 per 100 patient-years) treated with SOTYKTU, and 1 patient (0.8 per 100 patient-years) treated with placebo. Multidermatomal herpes zoster was reported in an immunocompetent patient. During PSO-1, PSO-2, and the open-label extension trial, the majority of patients who reported events of herpes zoster while receiving SOTYKTU were under 50 years of age. The impact of SOTYKTU on chronic viral hepatitis reactivation is unknown. Consider viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting and during therapy with SOTYKTU. If signs of reactivation occur, consult a hepatitis specialist. SOTYKTU is not recommended for use in patients with active hepatitis B or hepatitis C.
Tuberculosis (TB): In clinical trials, of 4 patients with latent TB who were treated with SOTYKTU and received appropriate TB prophylaxis, no patients developed active TB (during the mean follow-up of 34 weeks). One patient, who did not have latent TB, developed active TB after receiving 54 weeks of SOTYKTU. Evaluate patients for latent and active TB infection prior to initiating treatment with SOTYKTU. Do not administer SOTYKTU to patients with active TB. Initiate treatment of latent TB prior to administering SOTYKTU. Consider anti-TB therapy prior to initiation of SOTYKTU in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during treatment.
Malignancy including Lymphomas: Malignancies, including lymphomas, were observed in clinical trials with SOTYKTU. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with SOTYKTU, particularly in patients with a known malignancy (other than a successfully treated non-melanoma skin cancer) and patients who develop a malignancy when on treatment with SOTYKTU.
Rhabdomyolysis and Elevated CPK: Treatment with SOTYKTU was associated with an increased incidence of asymptomatic creatine phosphokinase (CPK) elevation and rhabdomyolysis compared to placebo.
Discontinue SOTYKTU if markedly elevated CPK levels occur or myopathy is diagnosed or suspected. Instruct patients to promptly report unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.
Laboratory Abnormalities: Treatment with SOTYKTU was associated with increases in triglyceride levels. Periodically evaluate serum triglycerides according to clinical guidelines during treatment. SOTYKTU treatment was associated with an increase in the incidence of liver enzyme elevation compared to placebo. Evaluate liver enzymes at baseline and thereafter in patients with known or suspected liver disease according to routine management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt SOTYKTU until a diagnosis of liver injury is excluded.
Immunizations: Prior to initiating therapy with SOTYKTU, consider completion of all age-appropriate immunizations according to current immunization guidelines including prophylactic herpes zoster vaccination. Avoid use of live vaccines in patients treated with SOTYKTU. The response to live or non-live vaccines has not been evaluated.
Potential Risks Related to JAK Inhibition: It is not known whether tyrosine kinase 2 (TYK2) inhibition may be associated with the observed or potential adverse reactions of Janus Kinase (JAK) inhibition. In a large, randomized, postmarketing safety trial of a JAK inhibitor in rheumatoid arthritis (RA), patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events, overall thrombosis, deep venous thrombosis, pulmonary embolism, and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. SOTYKTU is not approved for use in RA.
ADVERSE REACTIONS
Most common adverse reactions (≥
SPECIFIC POPULATIONS
Pregnancy: Available data from case reports on SOTYKTU use during pregnancy are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Report pregnancies to the Bristol Myers Squibb Company’s Adverse Event reporting line at 1-800-721-5072.
Lactation: There are no data on the presence of SOTYKTU in human milk, the effects on the breastfed infant, or the effects on milk production. SOTYKTU is present in rat milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SOTYKTU and any potential adverse effects on the breastfed infant from SOTYKTU or from the underlying maternal condition.
Hepatic Impairment: SOTYKTU is not recommended for use in patients with severe hepatic impairment.
SOTYKTU is available in 6 mg tablets.
Please see
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X, YouTube, Facebook and Instagram.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that future study results may not be consistent with the results to date, that Sotyktu (deucravacitinib) may not receive regulatory approval for the additional indication described in this release in the currently anticipated timeline or at all, any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether Sotyktu for such additional indication will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2023, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.
corporatefinancial-news
View source version on businesswire.com: https://www.businesswire.com/news/home/20241220275848/en/
Bristol Myers Squibb
Media Inquiries:
media@bms.com
Investors:
investor.relations@bms.com
Source: Bristol Myers Squibb
FAQ
What were the primary results of BMY's POETYK PsA-1 and PsA-2 Phase 3 trials for Sotyktu?
How long did BMY's Phase 3 trials for Sotyktu in psoriatic arthritis last?
What is the current approval status of BMY's Sotyktu?
What makes BMY's Sotyktu unique in the psoriatic arthritis treatment landscape?
What was the safety profile of BMY's Sotyktu in the Phase 3 trials?
